Analyst Price Target is $36.60
▲ +77.76% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Kiniksa Pharmaceuticals in the last 3 months. The average price target is $36.60, with a high forecast of $40.00 and a low forecast of $34.00. The average price target represents a 77.76% upside from the last price of $20.59.
Current Consensus is
Buy
The current consensus among 5 contributing investment analysts is to buy stock in Kiniksa Pharmaceuticals.
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.
Read More
